Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Yung Chih Wen, M.D.

Co-Author

This page shows the publications co-authored by Patrick Wen and Eudocia Lee.
Connection Strength

16.975
  1. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol. 2021 08 02; 23(8):1252-1260.
    View in: PubMed
    Score: 0.951
  2. Gender and sex disparity in cancer trials. ESMO Open. 2020 08; 5(Suppl 4):e000773.
    View in: PubMed
    Score: 0.887
  3. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol. 2020 05 15; 22(5):601-612.
    View in: PubMed
    Score: 0.874
  4. Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117.
    View in: PubMed
    Score: 0.833
  5. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
    View in: PubMed
    Score: 0.831
  6. Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? Neuro Oncol. 2018 07 05; 20(8):1144.
    View in: PubMed
    Score: 0.768
  7. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
    View in: PubMed
    Score: 0.767
  8. The Interface Between Neurology and Oncology. Neurol Clin. 2018 08; 36(3):xiii-xiv.
    View in: PubMed
    Score: 0.765
  9. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017 Jul 20; 35(21):2439-2449.
    View in: PubMed
    Score: 0.715
  10. Corticosteroids for peritumoral edema: time to overcome our addiction? Neuro Oncol. 2016 09; 18(9):1191-2.
    View in: PubMed
    Score: 0.674
  11. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
    View in: PubMed
    Score: 0.652
  12. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
    View in: PubMed
    Score: 0.615
  13. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
    View in: PubMed
    Score: 0.603
  14. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8.
    View in: PubMed
    Score: 0.518
  15. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9.
    View in: PubMed
    Score: 0.512
  16. Neurologic complications of cancer drug therapies. Continuum (Minneap Minn). 2012 Apr; 18(2):355-65.
    View in: PubMed
    Score: 0.498
  17. Response assessment in neuro-oncology. Curr Oncol Rep. 2011 Feb; 13(1):50-6.
    View in: PubMed
    Score: 0.230
  18. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
    View in: PubMed
    Score: 0.222
  19. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
    View in: PubMed
    Score: 0.216
  20. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun; 12(6):603-7.
    View in: PubMed
    Score: 0.215
  21. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res. 2020 04 15; 26(8):1820-1828.
    View in: PubMed
    Score: 0.213
  22. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010 Jan; 12(1):68-75.
    View in: PubMed
    Score: 0.213
  23. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608.
    View in: PubMed
    Score: 0.208
  24. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.202
  25. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
    View in: PubMed
    Score: 0.200
  26. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
    View in: PubMed
    Score: 0.194
  27. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
    View in: PubMed
    Score: 0.185
  28. Updates in the management of brain metastases. Neuro Oncol. 2016 08; 18(8):1043-65.
    View in: PubMed
    Score: 0.168
  29. Assessment of Brain Tumor Response: RANO and Its Offspring. Curr Treat Options Oncol. 2016 07; 17(7):35.
    View in: PubMed
    Score: 0.167
  30. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
    View in: PubMed
    Score: 0.159
  31. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
    View in: PubMed
    Score: 0.150
  32. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504.
    View in: PubMed
    Score: 0.149
  33. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
    View in: PubMed
    Score: 0.149
  34. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 01; 34(10):e87-9.
    View in: PubMed
    Score: 0.146
  35. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
    View in: PubMed
    Score: 0.145
  36. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
    View in: PubMed
    Score: 0.145
  37. Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8.
    View in: PubMed
    Score: 0.135
  38. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
    View in: PubMed
    Score: 0.133
  39. Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87.
    View in: PubMed
    Score: 0.133
  40. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
    View in: PubMed
    Score: 0.126
  41. Central nervous system complications of cancer therapy. J Support Oncol. 2012 Jul-Aug; 10(4):133-41.
    View in: PubMed
    Score: 0.125
  42. Epidemiology of brain metastases. Curr Oncol Rep. 2012 Feb; 14(1):48-54.
    View in: PubMed
    Score: 0.123
  43. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009 Oct; 11(5):550-5.
    View in: PubMed
    Score: 0.101
  44. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
    View in: PubMed
    Score: 0.061
  45. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 01 05; 24(1):64-77.
    View in: PubMed
    Score: 0.061
  46. Recurrent high-grade glioma. Curr Treat Options Neurol. 2010 Jul; 12(4):321-33.
    View in: PubMed
    Score: 0.055
  47. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.055
  48. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.054
  49. Local control after brain-directed radiation in patients with cystic versus solid brain metastases. J Neurooncol. 2019 Apr; 142(2):355-363.
    View in: PubMed
    Score: 0.050
  50. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 03; 126(3):511-518.
    View in: PubMed
    Score: 0.047
  51. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e33-e42.
    View in: PubMed
    Score: 0.046
  52. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521.
    View in: PubMed
    Score: 0.046
  53. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017 Aug 01; 3(8):1069-1077.
    View in: PubMed
    Score: 0.045
  54. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
    View in: PubMed
    Score: 0.039
  55. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
    View in: PubMed
    Score: 0.039
  56. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
    View in: PubMed
    Score: 0.039
  57. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8.
    View in: PubMed
    Score: 0.039
  58. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
    View in: PubMed
    Score: 0.038
  59. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.038
  60. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
    View in: PubMed
    Score: 0.037
  61. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
    View in: PubMed
    Score: 0.036
  62. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406.
    View in: PubMed
    Score: 0.034
  63. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16.
    View in: PubMed
    Score: 0.034
  64. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
    View in: PubMed
    Score: 0.034
  65. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.